4/A: Bausch Health Director Richard Mulligan Amends Filing to Reflect Stock Award

Richard Mulligan, a director at Bausch Health Companies Inc., amended a previous filing to report the acquisition of 35,360 common shares through a restricted stock unit (RSU) award.

Summary

• Richard Mulligan, a director of Bausch Health Companies Inc., filed an amendment to a previous Form 4.
• The amendment reports a transaction that occurred on May 17, 2024, where Mulligan acquired 35,360 common shares of Bausch Health.
• These shares were obtained through a restricted stock unit (RSU) award granted to non-employee directors.
• The RSUs have a grant date value of $250,000 and vest immediately prior to the Issuer's next Annual Meeting of Shareholders.
• Following the reported transaction, Mulligan beneficially owns 101,269 common shares.
• The filing was signed by Brianna M. Cetrulo, attorney-in-fact, on May 20, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard director compensation practices and aligns director interests with shareholders. There are no indications of negative news or concerns.

Positives

• The RSU award aligns the interests of non-employee directors with those of shareholders.
• The vesting schedule encourages continued service and commitment to the company's success.

Future Outlook

The RSUs vest immediately prior to the Issuer's next Annual Meeting of Shareholders, indicating a future event tied to the company's annual schedule.

Industry Context

Director compensation through equity awards is a common practice in publicly traded companies to align management's interests with those of shareholders. The $250,000 grant value is within a typical range for director compensation at companies of Bausch Health's size.

Comparison to Industry Standards

• Comparing Bausch Health's director compensation to peers like Teva Pharmaceutical Industries or Mylan (now Viatris), equity grants are a standard component.
• The specific value of $250,000 is within the range of what similar-sized pharmaceutical companies offer, though individual grants can vary based on company performance and director responsibilities.
• Companies like AbbVie or Johnson & Johnson, which are significantly larger, may offer higher compensation packages to their directors.

Stakeholder Impact

• Shareholders may view the RSU award positively as it aligns director interests with company performance.
• The award does not have a direct impact on employees, customers, suppliers, or creditors.

Next Steps

• The RSUs will vest immediately prior to the Issuer's next Annual Meeting of Shareholders.

Key Dates